Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Lung Injury
- Acute Respiratory Distress Syndrome
- COVID-19 Severe Pneumonia
- Pneumonia, Viral
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04369469
- Collaborators
- Not Provided
- Investigators
- Not Provided